Localized Dyskeratotic Plaque With Milia Associated With Sorafenib
June 2009 | Volume 8 | Issue 6 | 573 | Copyright © June 2009
Jeaneen A. Chappell MD, Nicole M. Burkemper MD, Natalie Semchyshyn MD
Abstract
Sorafenib, a multitargeted kinase inhibitor used for the treatment of unresectable hepatocellular carcinoma and advanced renal cell
carcinomas, received FDA approval in 2005. Since its introduction to the market, there have been various dermatologic side effects
reported in the literature, the most well known being hand-foot skin reaction. This article presents a case of an atypical localized
cutaneous eruption with an unusual course and protracted resolution time associated with sorafenib therapy. 
